...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Investigative radiology >The cost of developing imaging agents for routine clinical use.
【24h】

The cost of developing imaging agents for routine clinical use.

机译：开发用于常规临床用途的成像剂的成本。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of this study was to estimate the financial cost of developing new imaging agents for clinical use and to discuss the effects of these costs on the future clinical imaging agent environment. Publicly available financial data from the annual reports of major companies developing and selling imaging agents were examined and the data used to develop cost estimates. These estimates were compared with the in-depth data and analyses available for the development costs of therapeutic drugs. The cost of developing a drug for diagnostic imaging to commercialization is in the 100 dollars to 200 million dollars range, whereas a blockbuster imaging drug has current sales of 200 dollars to 400 million dollars. Most of these blockbuster imaging agents have been on the market for some time. The majority provide morphologic images with general indications in a slowly changing section of the market. Future agents will most likely address smaller markets and be in the rapidly developing molecular imaging field. The costs are high and are a significant brake on the development of imaging agents for commercialization. If new imaging agents are to realize their commercial potential, ways must be found to make the financials more attractive. The prices per dose are currently low so they must either be greatly increased for new imaging agents, with a corresponding increase in the value of the information they provide, or the use of imaging agents must be widened and/or their development made less costly in time and money. Without addressing these issues, the commercialization of new imaging agents will continue to be slow and may get slower. This will impact the progress of imaging agents toward use as validated biomarkers.
机译：这项研究的目的是估计开发用于临床的新型显像剂的财务成本，并讨论这些成本对未来临床显像剂环境的影响。审查了主要公司开发和销售成像剂的年度报告中可公开获得的财务数据，并将这些数据用于制定成本估算。这些估计值与用于治疗药物开发成本的深入数据和分析进行了比较。开发用于商业化诊断成像的药物的成本在100美元至2亿美元之间，而一鸣惊人的成像药物目前的销售额为200美元至4亿美元。这些重磅炸弹成像剂大多数已经在市场上销售了一段时间。大多数人在市场变化缓慢的区域中提供具有一般指示的形态图像。未来的代理商很可能会针对较小的市场，并处于快速发展的分子成像领域。成本很高，并且阻碍了用于商业化的显像剂的开发。如果新的成像剂要实现其商业潜力，必须找到使财务更具吸引力的方法。目前每剂的价格较低，因此对于新的显像剂，必须大幅提高其价格，同时其提供的信息价值也会相应增加，或者必须扩大显像剂的使用和/或降低其开发成本。时间和金钱。如果不解决这些问题，新的成像剂的商业化将继续缓慢并且可能变得越来越慢。这将影响显像剂在用作经过验证的生物标记物方面的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号